Research Biosimilars – All Products
ichorbio supplies a small but growing range of biosimilars for research use only (not for diagnostic or therapeutic use).
A-Z of our biosimilars based on target:
Complement Protein C5 Inhibitors
IL-12 / IL-23 Inhibitors
IL-6 Receptor Inhibitors
Integrin a4b7 Inhibitors
ichorbio has developed research grade versions of both nivolumab and pembrolizumab. Cemiplimab is the other FDA approved inhibitor of PD-1 and is in our product pipeline.
ichorbio has created research use versions of atezolizumab, avelumab. Durvalumab is the other FDA approved inhibitor of PD-L1.
TNF alpha inhibitors
There are currently three anti-TNF antibodies that have been approved to inhibit TNF alpha: infliximab, adalimumab and golimumab. ichorbio has developed two versions of adalimumab – a standard biosimilar and a Fc-silenced version. We’ve also developed a research grade infliximab biosimilar.
ichorbio has developed two VEGF inhibitors – Aflibercept and Bevacizumab. Our Bevacizumab biosimilar is also available in an Fc-silenced version.
ichorbio is releasing new research grade biosimilars on a weekly basis. If you have any specific requests for new products please contact us at email@example.com or LiveChat.